CompletedNCT05061719
Longer-term safety of lumateperone added to depression treatment
About this title
Read the official source — NCT05061719This study evaluated the safety of Lumateperone for people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety of Lumateperone for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 108 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: October 8, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 812
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Czechia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05061719
- Official title
Show the full official title
An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix, United States · Bentonville, United States · Little Rock, United States
92 more locations
- Rogers, United States
- Culver City, United States
- Glendale, United States
- Newport Beach, United States
- Oceanside, United States
- Redlands, United States
- Riverside, United States
- San Diego, United States
- Sherman Oaks, United States
- Temecula, United States
- Upland, United States
- Fort Lauderdale, United States
- Jacksonville, United States
- Orlando, United States
- Palm Bay, United States
- West Palm Beach, United States
- Atlanta, United States
- Decatur, United States
- Joliet, United States
- Overland Park, United States
- Gaithersburg, United States
- Boston, United States
- Flowood, United States
- Saint Charles, United States
- Berlin, United States
- Toms River, United States
- Brooklyn, United States
- Cedarhurst, United States
- Mount Kisco, United States
- Charlotte, United States
- Allentown, United States
- Media, United States
- Plymouth Meeting, United States
- Austin, United States
- Bellevue, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Novi Iskar, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Tsarev Brod, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Brno, Czechia
- Hostivice, Czechia
- Ostrava, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Helsinki, Finland
- Oulu, Finland
- Bad Homburg, Germany
- Freiburg im Breisgau, Germany
- Hamburg, Germany
- Mittweida, Germany
- Schwerin, Germany
- Westerstede, Germany
- Budapest, Hungary
- Debrecen, Hungary
- Gyöngyös, Hungary
- Guwahati, India
- Ahmedabad, India
- Jūnāgadh, India
- Vadodara, India
- Mysore, India
- Chhatrapati Sambhajinagar, India
- Nagpur, India
- Nashik, India
- Mumbai, India
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Gorlice, Poland
- Leszno, Poland
- Pruszcz Gdański, Poland
- Torun, Poland
- Wroclaw, Poland
- Bratislava, Slovakia
- Košice, Slovakia
- Rimavská Sobota, Slovakia
- Svidník, Slovakia
- Vranov nad Topľou, Slovakia
- Zlaté Moravce, Slovakia
- Ansan-si, South Korea
- Gwangju, South Korea
- Seoul, South Korea
- Lund, Sweden
- Stockholm, Sweden
- Czechia
Questions about this study
What did researchers investigate?
This study evaluated the safety of Lumateperone for people with depression.
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Did this study involve medication?
Yes. The study involved medication, including Lumateperone.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
